Name of issuer: Global Blood Therapeutics Inc.

Title of Class of Securities: Common Stock

CUSIP Number: 37890U108

Date of Event Which Requires Filing of this Statement: December 31, 2020

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)
☐ Rule 13d-1(c)
☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on the following page(s))
CUSIP No.: 37890U108

<table>
<thead>
<tr>
<th>1. NAME OF REPORTING PERSON</th>
<th>The Vanguard Group - 23-1945930</th>
</tr>
</thead>
<tbody>
<tr>
<td>I.R.S. IDENTIFICATION NO. OF ABOVE PERSON</td>
<td></td>
</tr>
</tbody>
</table>

2. CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

A.                                B. X

3. SEC USE ONLY

4. CITIZENSHIP OF PLACE OF ORGANIZATION

Pennsylvania

(For questions 5-8, report the number of shares beneficially owned by each reporting person with:

<table>
<thead>
<tr>
<th>5. SOLE VOTING POWER</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. SHARED VOTING POWER</td>
<td>46,133</td>
</tr>
<tr>
<td>7. SOLE DISPOSITIVE POWER</td>
<td>5,368,569</td>
</tr>
<tr>
<td>8. SHARED DISPOSITIVE POWER</td>
<td>91,913</td>
</tr>
</tbody>
</table>

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,460,482

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

N/A

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

8.84%

12. TYPE OF REPORTING PERSON

IA
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G
Under the Securities Act of 1934

Item 1(a) - Name of Issuer:
Global Blood Therapeutics Inc.

Item 1(b) - Address of Issuer's Principal Executive Offices:
400 East Jamie Court
Suite 101
South San Francisco, 94080

Item 2(a) - Name of Person Filing:
The Vanguard Group - 23-1945930

Item 2(b) – Address of Principal Business Office or, if none, residence:
100 Vanguard Blvd.
Malvern, PA 19355

Item 2(c) – Citizenship:
Pennsylvania

Item 2(d) - Title of Class of Securities:
Common Stock

Item 2(e) - CUSIP Number
37890U108

Item 3 - Type of Filing:
This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

Item 4 - Ownership:
(a) Amount Beneficially Owned:
5,460,482

(b) Percent of Class:
8.84%
(c) Number of shares as to which such person has:

(i) sole power to vote or direct to vote: 0

(ii) shared power to vote or direct to vote: 46,133

(iii) sole power to dispose of or to direct the disposition of: 5,368,569

(iv) shared power to dispose or to direct the disposition of: 91,913

Comments:

Item 5 - Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:
Not applicable

Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:
See Attached Appendix A

Item 8 - Identification and Classification of Members of Group:
Not applicable

Item 9 - Notice of Dissolution of Group:
Not applicable

Item 10 - Certification:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 8, 2021

By /s/ Christine M. Buchanan
Name: Christine M. Buchanan
Title: Principal
Appendix A

Subsidiary:
Vanguard Asset Management, Limited
Vanguard Fiduciary Trust Company
Vanguard Global Advisors, LLC
Vanguard Group (Ireland) Limited
Vanguard Investments Australia Ltd
Vanguard Investments Canada Inc.
Vanguard Investments Hong Kong Limited
Vanguard Investments UK, Limited

*Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G